Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366927 | 0.86 | CYP3A4 (0.44) | ALDH1A1TSHRHSD17B10CYP3A4RECQL | |
| SCHEMBL4046581 | 0.84 | GRM2 (0.40) | ALDH1A1TSHRHSD17B10CYP3A4RECQL | |
| SCHEMBL3922931 | 0.84 | POLB (0.53) | ALDH1A1TSHRCYP3A4POLBL3MBTL1 | |
| SCHEMBL17351119 | 0.84 | SPR (0.40) | ALDH1A1TSHRHSD17B10CYP3A4RECQL | |
| SCHEMBL11252986 | 0.83 | AKR1C4 (0.57) | ALDH1A1TSHRHSD17B10CYP3A4POLB | |
| SCHEMBL811037 | 0.82 | LMNA (0.46) | TSHRHSD17B10CYP3A4RECQLPOLB | |
| SCHEMBL5173533 | 0.82 | CYP3A4 (0.48) | HSD17B10CYP3A4POLBPARP1KMT2A | |
| SCHEMBL15129472 | 0.81 | CYP1A2 (0.38) | ALDH1A1TSHRHSD17B10CYP3A4RECQL | |
| SCHEMBL31145307 | 0.81 | L3MBTL1 (0.38) | ALDH1A1TSHRHSD17B10POLBL3MBTL1 | |
| SCHEMBL17350918 | 0.81 | L3MBTL1 (0.38) | ALDH1A1TSHRHSD17B10POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2906559-B1 | AZAINDOLINES | HOFFMANN LA ROCHE (CH) | 2017-02-08 | — | — | EP | claimed |
| US-9309248-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-04-12 | — | — | US | claimed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| US-20150266879-A1 | AZAINDOLINES | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | claimed |
| EP-2906559-A1 | AZAINDOLINES | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | claimed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | claimed |
| WO-2014056871-A1 | AZAINDOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | claimed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | claimed |
| US-20020025977-A1 | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives | NEUROGEN CORPORATION | 2002-02-28 | — | — | US | claimed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | claimed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | claimed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266879-A1 | AZAINDOLINES | AZI2, H1-5, CCNY | ALDH1A1 682/4885TSHR 512/4885HSD17B10 3739/4885 |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | ALDH1A1 1202/4885TSHR 3325/4885HSD17B10 4544/4885 |
| US-20020025977-A1 | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives | CRHR1, CRHR2, HTR2C | ALDH1A1 1438/4885TSHR 196/4885HSD17B10 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.